Long-acting injectable vs oral antipsychotics: trade-offs

Few decisions in chronic schizophrenia care matter more than the format of the medication. A daily pill puts the choice — and the responsibility — back in the patient's hands every morning. A long-acting injectable (LAI), given every 2 weeks to every 6 months depending on the formulation, takes that daily decision off the table for the entire dosing interval. Both approaches have real strengths. Both have real costs. And the decision is rarely black-and-white.

What LAIs are

An LAI is an antipsychotic formulated to be released slowly into the bloodstream after intramuscular or subcutaneous injection. Most are given by a clinician at intervals of 2 weeks to 6 months. Common LAIs include:

• First-generation: haloperidol decanoate, fluphenazine decanoate
• Second-generation: Risperdal Consta (every 2 weeks), Perseris (monthly subcutaneous), Invega Sustenna (monthly), Invega Trinza (3-monthly), Invega Hafyera (6-monthly), Abilify Maintena (monthly), Aristada (monthly to 2-monthly), Zyprexa Relprevv (2 or 4 weeks)

The relapse-prevention evidence

Across multiple meta-analyses and large naturalistic studies, LAIs reduce relapse and rehospitalisation rates compared to their oral equivalents. The most cited findings come from the Finnish nationwide cohort studies (Tiihonen et al., available via PubMed), which followed over 29,000 patients with schizophrenia for years and consistently showed lower hospitalisation rates among LAI users.

Randomised trials are more mixed. The PROACTIVE trial and the ACLAIMS trial showed smaller LAI advantages than the cohort studies — partly because RCT participants are already a relatively adherent group. The honest summary: LAIs particularly help patients whose oral adherence is poor, and the benefit is consistent in real-world populations even when smaller in research populations.

What LAIs do well

• Remove the daily question — particularly powerful for patients in the vulnerable post-discharge period
• Make missed doses immediately visible — if a patient doesn't show for an injection, the care team knows; missed pills are silent
• Reduce relapse in many real-world populations
• Can free patients from medication-related identity — no daily reminder of being "a patient"
• Improve adherence with no daily effort

What oral antipsychotics do well

• Allow rapid dose adjustment when symptoms change or side effects emerge
• Easy to discontinue or switch if a problem appears
• No clinic visit required for each dose
• Generally cheaper at the pharmacy counter as generics
• Preserve sense of patient agency — important for some patients' relationship with treatment

The trust question

An LAI is a commitment. Once the injection is given, the medication is in the body for the full dosing interval. If a serious side effect develops in week one of a monthly injection, the only options are supportive care and waiting. Oral medication can be stopped in a day. This is a real difference and should be discussed openly before any LAI is started.

Specific clinical situations

First-episode psychosis

Historically, LAIs were reserved for chronic patients who had failed oral therapy. That position is shifting. Several recent studies suggest LAIs in first-episode patients reduce relapse and protect against the cumulative damage of repeated psychotic episodes. Many early intervention services now offer LAIs as an early option, not a last resort.

After a hospitalisation

The post-discharge period is the highest-risk window for relapse. LAIs are particularly valuable here, both because adherence is often shaky after discharge and because the structure of regular injection appointments creates ongoing clinical contact.

Treatment-resistant schizophrenia

Clozapine — the gold-standard treatment-resistant medication — is not available as an LAI. For patients on clozapine, the daily oral question remains.

Pregnancy and breastfeeding

The long half-life of LAIs is a complication during pregnancy planning. Discontinuing an oral medication is straightforward; the residual effect of an LAI persists for weeks or months. This needs careful planning.

Practical issues

• Injection site reactions — usually mild, occasionally significant
• Need for clinic infrastructure — not every practice can deliver LAIs reliably
• Insurance and access — branded LAIs are expensive, though most are widely covered
• The first dose — most LAIs require a period of oral overlap before the depot reaches steady state; this needs to be explained clearly

How to think about the choice

Useful questions to bring to a prescriber:

• Have I had relapses related to missed doses of oral medication?
• How do I feel about the daily routine of taking pills?
• Do I have reliable access to a clinic for monthly visits?
• Am I planning a pregnancy in the next year?
• What dose adjustments are likely as I stabilise?
• If we tried an LAI, what's the back-out plan if something goes wrong?

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.